Trial reportDiabetologia2011
Intensive glucose control and risk of cancer in patients with type 2 diabetes.
Trial report in Diabetologia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00145925 (ADVANCE - Action in Diabetes and Vascular Disease), which is not on this map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Preventive and Therapeutic effects of Metformin in Cancer: A Meta- Analysis of RCT and Cohort Studies.Current cancer drug targets · 2026Pooled it
- GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.Diabetes, obesity & metabolism · 2025 · on this mapPooled it
- Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer, Second Report.Diabetology international · 2016Guideline
- Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Cancer prevention research (Philadelphia, Pa.) · 2014 · on this mapPooled it
- Diabetes Mellitus and Gastric Cancer: Correlation and Potential Mechanisms.Journal of diabetes research · 2023Review
- Long-term fasting glucose variability and risk of cancer in patients with type 2 diabetes mellitus: A retrospective population-based cohort study in Shanghai.Journal of diabetes · 2022Article
- History of lower-limb complications and risk of cancer death in people with type 2 diabetes.Cardiovascular diabetology · 2021Article
- Report of the Japan diabetes society/Japanese cancer association joint committee on diabetes and cancer, Second report.Cancer science · 2016Review
- Article
- Article
- Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer.Diabetes care · 2013Review
- Latest insights into the risk of cancer in diabetes.Journal of diabetes investigation · 2013Review
- Cancer metabolism as a therapeutic target: finding the right target(s) in the context of tumor heterogeneity, evolution, and metabolic plasticity.Oncology (Williston Park, N.Y.) · 2013Article
- Diabetes, insulin and cancer risk.World journal of diabetes · 2012Article
- Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data.Diabetologia · 2012Article
- Significantly increased risk of cancer in diabetes mellitus patients: A meta-analysis of epidemiological evidence in Asians and non-Asians.Journal of diabetes investigation · 2012Review
- Insulin therapy and cancer in type 2 diabetes.ISRN endocrinology · 2012Article
- HbA1C and cancer risk in patients with type 2 diabetes--a nationwide population-based prospective cohort study in Sweden.PloS one · 2012Article
- Diabetes, treatments for diabetes and their effect on cancer incidence and mortality: attempts to disentangle the web of associations.Diabetologia · 2011Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisType 2 diabetes has been associated with an increased risk of cancer. This study examines the effect of more vs less intensive glucose control on the risk of cancer in patients with type 2 diabetes.
methodsAll 11,140 participants from the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial (ClinicalTrials.gov NCT00145925) were studied. Cancer incidence and cancer mortality was compared in groups randomised to intensive or standard glucose control. Information on events during follow-up was obtained from serious adverse event reports and death certificates. HRs (95% CI) were calculated for all cancers, all solid cancers, cancer deaths and site-specific cancers.
resultsAfter a median follow-up of 5 years, 363 and 337 cancer events were reported in the intensive and standard control groups, respectively (incidence 1.39/100 person-years [PY] and 1.28/100 PY; HR 1.08 [95% CI 0.93-1.26]). The incidences of all solid cancers and cancer deaths were 1.25/100 PY and 0.55/100 PY in the intensive group and 1.15/100 PY and 0.63/100 PY in the standard group (HR 1.09[95% CI 0.93–1.27] for solid cancers, and 0.88 [0.71–1.10] for cancer death) [corrected].Across all the major organ systems studied, no significant differences in the cancer incidences were observed in the intensive and standard control groups. CONCLUSIONS/INTERPRETATIONS: More intensive glucose control achieved with a regimen that included greater use of gliclazide, insulin, metformin and other agents, did not affect the risk of cancer events or death in patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.